Thus, silencing of JNK and STAT5A/B appears to be involved in the anticancer effects of the HER-TKIs and inactivation of these signal effector molecules could therefore potentially serve as biological indicator for sensitivity of breast cancer cells against HER-TKIs. The gene discussed is STAT5A; the disease is breast carcinoma.